Table 3.
Univariate and multivariate analysis for factors associated with cardiac response.
| Characteristics | Univariate | Multivariate | ||
|---|---|---|---|---|
| OR (95% CI) | P-value | OR (95% CI) | P-value | |
| Age | 0.993 (0.972–1.014) | 0.498 | ||
| Duration between onset and diagnosis | 0.993 (0.981–1.005) | 0.252 | ||
| Involved light chains | 0.049 | |||
| AL-k | 1 | |||
| AL-λ | 1.869 (1.134–3.078) | |||
| NT-proBNP | 1.000 (1.00–1.000) | <0.001 | ||
| cTnl | 0.580 (0.233–1.445) | 0.242 | ||
| dFLC | 1.000 (1.00–1.000) | 0.072 | ||
| rFLC | 0.993 (0.983–1.002) | 0.149 | ||
| Mayo Stage 2012 | 0.851 | |||
| I | 1 | |||
| II | 0.753 (0.376–1.508) | |||
| III | 0.882 (0.462–1.687) | |||
| IV | 0.929 (0.476–1.813) | |||
| NYHA | 0.011 | |||
| I | 1 | |||
| Ii | 1.965 (1.106–3.490) | |||
| III | 1.391 (0.775–2.498) | |||
| IV | 0.477 (0.168–1.352) | |||
| Treatment | <0.001 | 0.098 | ||
| IMiD-containing | 1 | 1 | ||
| Melphalan-containing | 1.314 (0.373–4.626) | 0.994 (0.129–7.667) | ||
| Bortezomib-containing | 4.670 (1.566–17.572) | 3.967 (0.774–20.345) | ||
| Courses of treatment | <0.001 | <0.001 | ||
| Stage 1 (0–3) | 1 | 1 | ||
| Stage 2 (4–6) | 5.356 (2.829–10.141) | 1.888 (0.711–5.015) | ||
| Stage 3 (7–9) | 23.565 (12.337–45.012) | 8.860 (3.248–24.162) | ||
| Stage 4 (≥10) | 8.263 (2.614–26.116) | 9.232 (1.433–59.455) | ||
| Hematological response | <0.001 | 0.001 | ||
| CR/VGPR/PR | 1 | 1 | ||
| PD/NR/SD | 56.14 (13.42–234.82) | 0.067 (0.014–0.320) | ||
CI, confidence interval; NT-proBNP; N-terminal natriuretic peptide type B; cTnI, cardiac troponin I; dFLC, uninvolved free light chain; rFLC, free light chain ratio; IMiD, immunomodulatory drug; CR, complete response; VGPR, very good partial response; PR, partial response; PD, partial disease; NR, no response; SD, stable disease.